- $23.82bn
- $25.62bn
- $5.02bn
- 87
- 18
- 97
- 75
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 10-K |
Standards: | USG | USG | USG | USG |
Status: | Final | Final | Final | Final |
Revenue | ||||
Total Revenue | 4,348 | 4,700 | 4,870 | 5,021 |
Cost of Revenue | ||||
Gross Profit | 2,510 | 2,713 | 2,760 | 2,901 |
Selling / General / Administrative Expenses | ||||
Research And Development | ||||
Total Operating Expenses | 3,397 | 3,659 | 3,758 | 3,881 |
Operating Profit | 951 | 1,041 | 1,112 | 1,140 |
Total Net Non Operating Interest Income / Expense | ||||
Other Net Non Operating Costs | ||||
Net Income Before Taxes | 950 | 1,047 | 1,113 | 1,096 |
Provision for Income Taxes | ||||
Net Income After Taxes | 724 | 861 | 845 | 839 |
Net Income Before Extraordinary Items | ||||
Net Income | 724 | 861 | 845 | 839 |
Income Available to Common Shareholders Excluding Extraordinary Items | ||||
Income Available to Common Shareholders Including Extraordinary Items | ||||
Diluted Net Income | 724 | 861 | 845 | 839 |
Diluted Weighted Average Shares | ||||
Basic EPS Including Extraordinary Items | ||||
Diluted EPS Including Extraordinary Items | ||||
Diluted EPS Excluding Extraordinary Items | ||||
Normalised Income Before Taxes | ||||
Normalised Income After Taxes | ||||
Normalised Income Available to Common Shareholders | ||||
Diluted Normalised EPS | 3 | 3.5 | 3.46 | 3.44 |
Dividends per Share |